Stocks GlaxoSmithKline PLC

More

  • Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • U.S. stock futures were lower this morning, ahead of the prospect for greater volatility and volume on the final Friday of the year for quadruple witching.

  • LONDON, Dec 16- AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than $800 million in the country over the next 10 years, it said on Wednesday. "We don't want to have drugs that are approved in the U.S. and elsewhere and it then takes another five or six years to bring them to patients...

  • *Kennametal, 3 M slump after forecast cuts. *Valeant up on distribution deal with Walgreens. "It's been hard to predict where the market is going on a day-to-day basis," said Scott Brown, chief economist at Raymond James in St. Petersburg, Florida.

  • *Kennametal, 3 M slump after forecast cuts. *Qualcomm up on raised guidance. *Valeant up on distribution deal with Walgreens.

  • *Traders see an 83 percent chance of a rate hike this week, according to the CME Group's FedWatch program. *Amgen shares were up nearly 3 percent at $162.70 in premarket trading. *Kennametal slumped 17 percent to $21.22 after it cut its 2016 profit and revenue forecasts, citing weakness and volatility in its core markets and lower oil prices.

  • *Sanofi in talks to acquire Boehringer consumer health. *Boehringer to buy Sanofi's animal health arm Merial. PARIS/ LONDON, Dec 15- Sanofi and Boehringer Ingelheim are in exclusive talks over a $20 billion swap of the French pharmaceuticals company's animal health business for the family-owned German group's consumer health operation.

  • Dec 14- Amgen Inc on Monday said it had reached a deal with British drugmaker GlaxoSmithKline to reacquire the sales rights to three of its products in 48 countries, including Australia as well as markets in Asia, South America and Europe. Amgen will make undisclosed milestone payments to Glaxo upon signing and the successful transition of the products back to...

  • Dec 8- China's food and drug regulator said late on Monday it had rejected applications for 13 new drugs, citing false or incomplete trial data, as the government toughens enforcement of quality standards. The China Food and Drug Administration last month also rejected applications by eight Chinese companies for inadequate trial data related to generic...

  • LONDON, Dec 7- European shares rose on Monday to climb back up from three-week lows reached last week, although Electrolux slumped after its deal to buy General Electric's appliance business fell through. The broader European stock markets were supported by a rise in major healthcare stocks, with Novartis advancing on positive results for a...

  • China's anti-corruption drive has knocked 1.0-1.5 percent off GDP annually over the past two years and continues to hit the economy, says BNP Paribas.

  • *Arcelor Mittal falls after Citigroup downgrade. LONDON, Dec 2- A key European benchmark index closed near three-month highs on Wednesday, with expectations of new European Central Bank stimulus measures providing support. "The stock markets are still running up off the back of the euro, and expectations that ECB head Mario Draghi will announce new easing...

  • Euro

    European equities closed the session mixed Wednesday as investors digested inflation numbers and contemplated the possibility of further stimulus.

  • *Arcelor Mittal falls after Citigroup downgrade. LONDON, Dec 2- European shares rose on Wednesday, buoyed by expectations of new stimulus measures from the European Central Bank, while broker recommendations helped healthcare stocks to outperform. "The stock markets are still running up off the back of the euro, and expectations that ECB head Mario Draghi will...

  • *Zodiac Aerospace falls on downgrade from Exane. LONDON, Dec 2- European shares rose on Wednesday, buoyed by expectations of new economic stimulus measures from the European Central Bank, while healthcare stocks outperformed on some bullish broker recommendations. Roche rose 1.2 percent after Citigroup upgraded it to "buy" from "hold" while Morgan Stanley...

  • *Local drugs intensify competition as China squeezes prices. SHANGHAI, Nov 29- China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and aging population. That has made China a sweet spot for Denmark's Novo Nordisk; the world's biggest...

  • *GSK cut 40 pct of China sales reps after bribery scandal. SHANGHAI, Nov 26- GlaxoSmithKline Plc has cut 40 percent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record $490 million fine in 2014.. The British firm is gambling on a new, cleaner image to reboot its...

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 23- Pfizer Inc's looming deal to buy Botox maker Allergan Plc for more than $150 billion will cap a record-breaking run for mergers and acquisitions in the healthcare sector, taking the cumulative value of deals in 2015 to more than $600 billion. Pfizer's tax-driven takeover of Allergan, which people familiar with the matter said won board approval on...

  • Nov 20- Novartis AG said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said. Tafinlar and Mekinist are among cancer drugs...